Chronic Urticaria or Hives Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

July 2022 | 118 pages | ID: CF6E284A18ECEN
Global Markets Direct

Abstracts

Chronic Urticaria or Hives Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Urticaria Or Hives - Drugs In Development, 2022, provides an overview of the Chronic Urticaria Or Hives (Dermatology) pipeline landscape.

Chronic urticaria also known as hives, are an outbreak of swollen, pale red bumps, patches, or welts on the skin that appear suddenly either as a result of allergies, or for other reasons. The main symptom is itchy rashes. Chronic urticaria occurs when histamine and other chemicals are released from under the skin's surface, causing the tissues to swell. Predisposing factors include stress, caffeine, warm temperatures, alcohol and insect bites and stings. Treatment includes antihistamines and corticosteroids.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chronic Urticaria Or Hives - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Chronic Urticaria Or Hives (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Urticaria Or Hives (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Chronic Urticaria Or Hives and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Unknown stages are 10, 11, 11, 1, 1, 12 and 1 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Chronic Urticaria Or Hives (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Urticaria Or Hives (Dermatology).
• The pipeline guide reviews pipeline therapeutics for Chronic Urticaria Or Hives (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Chronic Urticaria Or Hives (Dermatology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Chronic Urticaria Or Hives (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Urticaria Or Hives (Dermatology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Chronic Urticaria Or Hives (Dermatology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Chronic Urticaria Or Hives (Dermatology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and @Scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Chronic Urticaria Or Hives - Overview
Chronic Urticaria Or Hives - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Chronic Urticaria Or Hives - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Chronic Urticaria Or Hives - Companies Involved in Therapeutics Development
Chronic Urticaria Or Hives - Drug Profiles
Chronic Urticaria Or Hives - Dormant Projects
Chronic Urticaria Or Hives - Discontinued Products
Chronic Urticaria Or Hives - Product Development Milestones
Featured News & Press Releases
Jul 21, 2022: Celldex announces first patient dosed in phase 2 study of barzolvolimab in patients with chronic inducible urticaria
Jul 03, 2022: Celldex Therapeutics presents positive interim data from barzolvolimab phase 1b study in chronic spontaneous urticaria at EAACI 2022
Jun 21, 2022: Celldex announces first patient dosed in phase 2 study of barzolvolimab in patients with chronic spontaneous urticaria
May 29, 2022: United BioPharma receives TFDA approval for phase 2 IND for UB-221 to treat chronic spontaneous urticaria
May 19, 2022: Celldex announces acceptance of abstract for barzolvolimab phase 1b results in chronic spontaneous urticaria for late-breaking presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2022
Mar 26, 2022: Late-breaking phase 3 data at AAD 2022 show Dupixent (dupilumab) significantly improved signs and symptoms of prurigo nodularis
Mar 01, 2022: Miravo Healthcare announces the Canadian commercial launch of Blexten for patients 4 years of age and older
Feb 26, 2022: Late-breaking phase 3 data at 2022 AAAAI Annual Meeting show Dupixent (dupilumab) significantly reduced itch and hives in patients with chronic spontaneous urticaria
Feb 18, 2022: Update on ongoing Dupixent (dupilumab) chronic spontaneous urticaria Phase 3 program
Feb 01, 2022: Positive Dupixent (dupilumab) data across five diseases with underlying type 2 inflammation to be presented at 2022 AAAAI Annual Meeting
Dec 20, 2021: Novartis provides an update on Phase III ligelizumab (QGE031) studies in chronic spontaneous urticaria (CSU)
Dec 01, 2021: Mirae Cell Bio establishes stem cell treatment theory for atopic dermatitis and chronic urticaria
Nov 30, 2021: Allakos announces expansion of lirentelimab development into atopic dermatitis, chronic spontaneous urticaria and asthma
Nov 25, 2021: Taiho Pharmaceutical: Announcement of new release of 'Vilanoa OD Tablets 20mg' for allergic diseases
Oct 01, 2021: Novartis’ remibrutinib displays quick disease control in urticaria trial
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Chronic Urticaria Or Hives, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Chronic Urticaria Or Hives - Pipeline by Allakos Inc, 2022
Chronic Urticaria Or Hives - Pipeline by Alvotech ehf, 2022
Chronic Urticaria Or Hives - Pipeline by Amgen Inc, 2022
Chronic Urticaria Or Hives - Pipeline by BCN Peptides SA, 2022
Chronic Urticaria Or Hives - Pipeline by BiosanaPharma BV, 2022
Chronic Urticaria Or Hives - Pipeline by Bioviz Technologies Pvt Ltd, 2022
Chronic Urticaria Or Hives - Pipeline by Celldex Therapeutics Inc, 2022
Chronic Urticaria Or Hives - Pipeline by Celltrion Inc, 2022
Chronic Urticaria Or Hives - Pipeline by CoSci Med-Tech Co Ltd, 2022
Chronic Urticaria Or Hives - Pipeline by Curateq Biologics Pvt Ltd, 2022
Chronic Urticaria Or Hives - Pipeline by DongKoo Bio & Pharma Co Ltd, 2022
Chronic Urticaria Or Hives - Pipeline by Faes Farma SA, 2022
Chronic Urticaria Or Hives - Pipeline by Genentech USA Inc, 2022
Chronic Urticaria Or Hives - Pipeline by Genu Pharma Co Ltd, 2022
Chronic Urticaria Or Hives - Pipeline by GI Innovation Co Ltd, 2022
Chronic Urticaria Or Hives - Pipeline by Glenmark Pharmaceuticals Ltd, 2022
Chronic Urticaria Or Hives - Pipeline by GSK plc, 2022
Chronic Urticaria Or Hives - Pipeline by Inmagene Biopharmaceuticals Ltd, 2022
Chronic Urticaria Or Hives - Pipeline by KeifeRx LLC, 2022
Chronic Urticaria Or Hives - Pipeline by Kiniksa Pharmaceuticals Ltd, 2022
Chronic Urticaria Or Hives - Pipeline by Kyowa Kirin Co Ltd, 2022
Chronic Urticaria Or Hives - Pipeline by Leo Pharma AS, 2022
Chronic Urticaria Or Hives - Pipeline by Luye Pharma Group Ltd, 2022
Chronic Urticaria Or Hives - Pipeline by Mabtech Ltd, 2022
Chronic Urticaria Or Hives - Pipeline by Mirae Cell Bio Co Ltd, 2022
Chronic Urticaria Or Hives - Pipeline by Mycenax Biotech Inc, 2022
Chronic Urticaria Or Hives - Pipeline by Novartis AG, 2022
Chronic Urticaria Or Hives - Pipeline by Oneness Biotech Co Ltd, 2022
Chronic Urticaria Or Hives - Pipeline by OrchestratePharma GmbH, 2022
Chronic Urticaria Or Hives - Pipeline by PharmAbcine Inc, 2022
Chronic Urticaria Or Hives - Pipeline by Principia Biopharma Inc, 2022
Chronic Urticaria Or Hives - Pipeline by RAPT Therapeutics Inc, 2022
Chronic Urticaria Or Hives - Pipeline by Regeneron Pharmaceuticals Inc, 2022
Chronic Urticaria Or Hives - Pipeline by Shanghai Pharmaceuticals Holding Co Ltd, 2022
Chronic Urticaria Or Hives - Pipeline by Siolta Therapeutics Inc, 2022
Chronic Urticaria Or Hives - Pipeline by STERO Biotechs Ltd, 2022
Chronic Urticaria Or Hives - Pipeline by Synermore Biologics Co Ltd, 2022
Chronic Urticaria Or Hives - Pipeline by Taiho Pharmaceutical Co Ltd, 2022
Chronic Urticaria Or Hives - Pipeline by Teva Pharmaceutical Industries Ltd, 2022
Chronic Urticaria Or Hives - Pipeline by Third Harmonic Bio Inc, 2022
Chronic Urticaria Or Hives - Pipeline by Tianchen Biopharmaceutical (Suzhou) Co Ltd, 2022
Chronic Urticaria Or Hives - Pipeline by TLL Pharmaceutical LLC, 2022
Chronic Urticaria Or Hives - Pipeline by United Biomedical Inc, 2022
Chronic Urticaria Or Hives - Pipeline by United BioPharma Inc, 2022
Chronic Urticaria Or Hives - Pipeline by ValenzaBio Inc, 2022
Chronic Urticaria Or Hives - Dormant Projects, 2022
Chronic Urticaria Or Hives - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Chronic Urticaria Or Hives, 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022